Using tumor DNA tests to time treatment for HPV throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can do daily activities at a good level (ECOG 0–2).
- Your cancer is HPV-16 squamous cell cancer in the oropharynx (throat) or HPV-16 head and neck cancer with no known starting point; HPV must be confirmed by a specific lab test (in-situ hybridization).
- Before surgery, your HPV blood test (ctDNA) must be detectable at least 50 copies per mL using the Naveris digital PCR test.
- You must have had surgery to remove all visible cancer, and scans after surgery should show no visible disease.
- After surgery, you must have two blood tests (about 2–6 weeks after surgery) that are both negative (less than 1 copy per mL).
- Your pathology (surgical tissue results) must match certain higher-risk features (Arm A or Arm B), such as specific lymph node spread patterns, lymph/nerve invasion, or margin concerns.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
This study looks at blood samples to find markers that may predict how well treatment works for HPV-positive throat cancer. It aims to help doctors tailor treatment in the future.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.